Apitegromab
- Generic Name
- Apitegromab
- Drug Type
- Biotech
- CAS Number
- 2278276-46-1
- Unique Ingredient Identifier
- UZ54216N0Y
- Background
Apitegromab is under investigation in clinical trial NCT03921528 (An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy).
EAP of Apitegromab for Patients With Spinal Muscular Atrophy
- Conditions
- SMA
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Scholar Rock, Inc.
- Registration Number
- NCT06877689
Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese
- Conditions
- Overweight and Obesity
- Interventions
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Scholar Rock, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT06445075
- Locations
- πΊπΈ
ProSciento CRU, Chula Vista, California, United States
πΊπΈAdventHealth Translational Research Institute, Orlando, Florida, United States
πΊπΈGreat Lakes Clinical Trials, LLC d/b/a Flourish Research, Chicago, Illinois, United States
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
- Conditions
- Spinal Muscular AtrophySpinal Muscular Atrophy Type 3Spinal Muscular Atrophy Type 2SMANeuromuscular DiseasesMuscular AtrophyAtrophyMuscular Atrophy, SpinalNeuromuscular ManifestationsAnti-myostatin
- Interventions
- First Posted Date
- 2022-11-25
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Scholar Rock, Inc.
- Target Recruit Count
- 238
- Registration Number
- NCT05626855
- Locations
- π§πͺ
UZ Gent, Gent, Belgium
π§πͺCHR Citadelle, Liege, Belgium
π«π·Hopital Trousseau - I-Motion, Paris, France
Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam
- Conditions
- Spinal Muscular AtrophyNeuromuscular DiseasesAtrophyMuscular Atrophy, SpinalAnti-myostatinSpinal Muscular Atrophy Type 3Spinal Muscular Atrophy Type 2SMAMuscular AtrophyNeuromuscular Manifestations
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Scholar Rock, Inc.
- Target Recruit Count
- 188
- Registration Number
- NCT05156320
- Locations
- πΊπΈ
Oregon Health & Sciences University, Portland, Oregon, United States
πΊπΈChildren's Hospital Colorado, Aurora, Colorado, United States
πΊπΈChildren's Hospital of Los Angeles, Los Angeles, California, United States
An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy
- Conditions
- Spinal Muscular AtrophySpinal Muscular Atrophy Type 2Neuromuscular DiseasesMuscular AtrophySMASpinal Muscular Atrophy Type 3AtrophyMuscular Atrophy, SpinalNeuromuscular Manifestations
- Interventions
- First Posted Date
- 2019-04-19
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Scholar Rock, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT03921528
- Locations
- πΊπΈ
Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States
π³π±Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
πΊπΈBoston Children's Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.